March 2008
Worldwide Biotech;Mar2008, Vol. 20 Issue 3, p5
Trade Publication
This article deals with the clinical trial initiated by M's Science Corporation (MSC), a clinical stage discovery and development company, in Europe with its lead product SA4503 for the treatment of stroke. The target number of patients for this study is 60. The trial aims to evaluate the safety of SA4503 among stroke patients. Particular focus is given to the mechanism of action of SA4503. Comments form Shiro Mita, chairman and chief executive officer (CEO), are included.


Related Articles

  • Journal Anniversary Symposium 2010 Dedicated to Europe/Japan Stroke Research Cooperation. Hennerici, M. G.; Minematsu, K. // Cerebrovascular Diseases;Nov2010, Vol. 30 Issue 6, p537 

    No abstract available Copyright © 2010 S. Karger AG, Basel

  • Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. Furlan, Anthony; Higashida, Randall; Wechsler, Lawrence; Gent, Michael; Rowley, Howard; Kase, Carlos; Pessin, Michael; Ahuja, Arvind; Callahan, Fred; Clark, Wayne M.; Silver, Frank; Rivera, Frank; Furlan, A; Higashida, R; Wechsler, L; Gent, M; Rowley, H; Kase, C; Pessin, M; Ahuja, A // JAMA: Journal of the American Medical Association;12/1/99, Vol. 282 Issue 21, p2003 

    Context: Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed.Objective: To determine the clinical efficacy...

  • Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice. Gladstone, David J.; Black, Sandra E. // CMAJ: Canadian Medical Association Journal;8/7/2001, Vol. 165 Issue 3, p311 

    Tissue plasminogen activator (tPA) injected intravenously within 3 hours of symptom onset has emerged as a treatment option for acute ischemic stroke. Although controversial and not universally accepted, its use in carefully selected patients is supported by evidence from randomized controlled...

  • Results of a UK questionnaire of diagnosis and treatment in cervical artery dissection. Menon, R. K.; Markus, H. S.; Norris, J. W. // Journal of Neurology, Neurosurgery & Psychiatry;May2008, Vol. 79 Issue 5, p612 

    The article discusses the results of a postal questionnaire of diagnosis and treatment in cervical artery dissection distributed to members of the British Association of Stroke Physicians in Great Britain. There are no randomised trials of any treatment regimen in cervical dissection. This...

  • Human stem cell therapy in ischaemic stroke: a review. Banerjee, Soma; Williamson, Deborah; Habib, Nagy; Gordon, Myrtle; Chataway, Jeremy // Age & Ageing;Jan2011, Vol. 40 Issue 1, p7 

    Stroke is a leading cause of death and disability. Globally, 15 million people suffer a stroke each year, of whom more than 5 million die, and a further 5 million are left permanently disabled. Current treatment options offer modest benefits, and there is a pressing need for new and effective...

  • Baseline NIH Stroke Scale Responses Estimate the Probability of Each Particular Stroke Subtype. Leira, E. C.; Adams Jr., H. P.; Rosenthal, G. E.; Torner, J. C. // Cerebrovascular Diseases;Dec2008, Vol. 26 Issue 6, p573 

    Background: Emergency treatment of ischemic stroke should ideally be mechanism specific, but acute subtype diagnosis is problematic. Since different subtypes often are associated with specific patterns of neurological deficits, we hypothesize that scores on baseline NIH stroke scale (NIHSS)...

  • Safety and Efficacy of IV-TPA for Ischaemic Stroke in Clinical Practice – A Bayesian Analysis. O'Rourke, Killian E. T.; Walsh, Cathal D.; Kelly, Peter J. // Cerebrovascular Diseases;Dec2009, Vol. 28 Issue 6, p572 

    Background: Observational studies of new treatments in routine practice are clinically important but may be limited by bias. We used a Bayesian approach to interpret and sequentially combine phase 4 studies of IV-TPA within 3 h for acute ischaemic stroke to quantify the cumulative evidence for...

  • Pathology May Help Decision Making in Asymptomatic Carotid Disease. Sangiorgi, Giuseppe // Journal of Interventional Cardiology;Jun2007, Vol. 20 Issue 3, p231 

    The article examines the effectiveness of carotid endarterectomy in preventing stroke. The author cites several clinical trials that showed a reduction in stroke incidence following carotid endarterectomy that include the North American Symptomatic Carotid Surgery Trial (NASCET) and the European...

  • IV t-PA Influences Infarct Volume in Minor Stroke: A Pilot Study. Villringer, Kersten; Grittner, Ulrike; Schaafs, Lars-Arne; Nolte, Christian H.; Audebert, Heinrich; Fiebach, Jochen B. // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Background: There is an ongoing debate whether stroke patients presenting with minor or moderate symptoms benefit from thrombolysis. Up until now, stroke severity on admission is typically measured with the NIHSS, and subsequently used for treatment decision. Hypothesis: Acute MRI lesion...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics